Compare AbCellera Biologics Inc (ABCL) vs Clorox Co (CLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Clorox Co — how do they compare? AbCellera Biologics Inc trades at $10.35 (market cap $2.99B), while Clorox Co trades at $108.39 (market cap $13.09B). The key difference: Clorox Co is far larger — about 4.4× AbCellera Biologics Inc's market cap, and Clorox Co pays a 4.62% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CLX | |
|---|---|---|
Market Cap | $2.99B | $13.09B |
Sector | Health | Consumer Staples |
52-Week High | $9.76 | $127.16 |
52-Week Low | $2.78 | $86.12 |
Enterprise Value | $2.58B | $18.47B |
Dividend Yield | — | 4.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.
The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.
Clorox (CLX) trades at $105.69, down 1.87% on the day, with a mixed technical picture showing bullish moving averages but overbought RSI signals. Recent Q4 2026 earnings beat expectations with EPS of $1.66 versus $1.64 estimated, though revenue trends remain pressured by inflation and consumer value-seeking. The company increased its quarterly dividend to $1.25 per share, signaling confidence in cash flow stability.
Outlook is cautious amid margin pressures and competitive threats, with Wall Street largely neutral (69% hold rating). The consensus price target of $97.50 suggests limited upside from current levels, while debt-to-asset ratio rising to 66.4% in 2026 highlights balance sheet risks. Investment appeal hinges on successful cost management and category recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →
